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Abstract
Introduction: Pulmonary arterial hypertension is a major cause of mortality in systemic sclerosis. N-terminal pro-
brain natriuretic peptide (NT-proBNP) has emerged as a candidate biomarker that may enable the early detection
of systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). The objective of our study was to
incorporate NT-proBNP into a screening algorithm for SSc-PAH that could potentially replace transthoracic
echocardiography (TTE) as a more convenient and less costly “first tier” test.
Methods: NT-proBNP levels were measured in patients from four clinical groups: a group with right heart catheter
(RHC)-diagnosed SSc-PAH before commencement of therapy for PAH; a group at high risk of SSc-PAH based on
TTE; a group with interstitial lung disease; and systemic sclerosis (SSc) controls with no cardiopulmonary
complications. NT-proBNP levels were compared by using ANOVA and correlated with other clinical variables by
using simple and multiple linear regression. ROC curve analyses were performed to determine the optimal cut
point for NT-proBNP and other clinical variables in prediction of PAH.
Results: NT-proBNP was highest in the PAH group compared with other groups (P < 0.0001), and higher in the
risk group compared with controls (P < 0.0001). NT-proBNP was positively correlated with systolic pulmonary artery
pressure (PAP) on TTE (P < 0.0001), and mean PAP (P = 0.013), pulmonary vascular resistance (P = 0.005), and mean
right atrial pressure (P = 0.006) on RHC. A composite model wherein patients screened positive if NT-proBNP was ≥
209.8 pg/ml, and/or DLCOcorr was < 70.3% with FVC/DLCOcorr ≥ 1.82, had a sensitivity of 100% and specificity of
77.8% for SSc-PAH.
Conclusion: We have proposed a screening algorithm for SSc-PAH, incorporating NT-proBNP level and PFTs. This
model has high sensitivity and specificity for SSc-PAH and, if positive, should lead to TTE and confirmatory testing
for PAH. This screening algorithm must be validated prospectively.
Introduction
Pulmonary arterial hypertension (PAH) is a major cause
of mortality in systemic sclerosis (SSc), accounting for
approximately 30% of SSc-related deaths [1,2]. Despite
the use of advanced pulmonary vasodilator therapies,
SSc-PAH has 1- and 3-year survival rates of 78% and
47%, respectively [3]. In its earliest stages, SSc-PAH is
often asymptomatic or minimally symptomatic. There-
fore, patients often present late in the natural history of
the disease, and more than two thirds are in World
Health Organisation functional class (WHO-FC) III and
IV at presentation [3-7]. Mounting evidence suggests
that earlier detection confers a survival advantage, with
a 3-year survival of 70% in those treated in WHO-FC I
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and II, compared with 3-year survival rates of 50% and
20% in those who are in WHO-FC III or IV, respec-
tively, at diagnosis [3]. In addition, earlier commence-
ment of treatment has been shown to delay the
progression of SSc-PAH and lead to improvement in
functional class [8,9]. Further, recent evidence has
emerged showing that systematic detection programs for
SSc-PAH improve the long-term survival of patients
when compared with a routine care model that uses
signs and symptoms to guide investigations, with an 8-
year survival rate of 64% in systematic detection pro-
grams compared with only 17% in routine care [10].
Current recommendations from the American College
of Cardiology Foundation and American Heart Associa-
tion (ACCF/AHA), European Society of Cardiology and
European Respiratory Society (ESC/ERS), and National
Pulmonary Hypertension Centres of the UK and Ireland
are for annual transthoracic echocardiography (TTE) in
SSc patients, with the latter also recommending mea-
surement of diffusing capacity of the lung for carbon
monoxide (DLCO) in patients with limited SSc [11-13].
Collectively, these tests may be expensive, resource and
labor intensive, technically challenging, and inconvenient
for patients.
The reliance on echocardiography has important lim-
itations. Pulmonary artery systolic pressure (sPAPTTE)
cannot be measured on echocardiography in 20% to
39% of patients because of absent tricuspid regurgitation
and/or insufficient image quality, including up to 29% of
patients subsequently found to have pulmonary hyper-
tension at right-heart catheterization (RHC) [14-16]. A
wide range exists in the reported sensitivities and speci-
ficities for echocardiography in PAH/PH (39% to 100%
and 42% to 97%, respectively), as well as an inverse rela-
tion between the specificity and sensitivity of echocar-
diography for identifying patients with PAH/PH-SSc
[14]. A study by Hsu et al. [17] showed a right ventricu-
lar systolic pressure (RVSP) of 47 mm Hg to have a sen-
sitivity of 58% and specificity of 96% for SSc-PAH. Thus,
ongoing interest remains in developing methods of non-
invasive screening that could improve the sensitivity of
current screening methods.
Currently, RHC is the only confirmatory test for PAH.
However, because of its invasive nature, RHC is not a
feasible screening tool for the SSc population. Therefore,
the goal in SSc-PAH detection is to reserve RHC for
those patients with a high clinical suggestion of PAH,
and to use less-invasive screening tools to risk stratify
patients for further assessment with RHC.
Blood biomarkers of PAH, either alone, or in combi-
nation with other noninvasive screening investigations,
may enable the risk stratification of patients with SSc
while potentially reducing the cost and inconvenience of
screening for PAH in SSc. N-Terminal pro-brain
natriuretic peptide (NT-proBNP) is one candidate bio-
marker of SSc-PAH. NT-proBNP is a 76-amino acid
polypeptide that is released along with BNP, by cardiac
myocytes, in response increased ventricular wall stress,
as typically occurs with volume overload and ventricular
contractile dysfunction [18]. When compared with BNP,
NT-proBNP is more sensitive to early increases in
sPAPTTE, has greater stability as a biomarker, and its
assay has good internal validity and reproducibility
[19,20]. In a case-control study, Mukherjee et al. [20]
showed a mean value of NT-proBNP in patients with
and without pulmonary arterial hypertension of 3,365
and 347 pg/ml, respectively, with a cut-off value of 395
pg/ml having a sensitivity of 69% and specificity of 100%
for identification of SSc-PAH. Allanore et al. [21] found
that NT-proBNP levels at more than 97% of manufac-
turer-provided normal levels, particularly when com-
bined with a DLCO/VA < 70%, could predict the
development of PAH in eight patients of a cohort of
101 patients over a 36-month period of follow-up.
The objective of our study was to determine the role
of NT-proBNP as a screening biomarker for incident
SSc-PAH and to evaluate the effect of incorporating this
novel biomarker into a screening model for SSc-PAH.
Materials and methods
Study population
Patients were selected from the Australian Scleroderma
Cohort Study (ASCS). The ASCS is a multicenter study
of risk and prognostic factors for cardiopulmonary out-
comes in SSc. All patients fulfill either ACR, or Leroy
and Medsger criteria for SSc [22,23]. All patients
undergo an annual clinical assessment, TTE, and PFT,
and have sera collected and stored. Any patient identi-
fied by noninvasive screening as having possible PAH
(sPAPTTE ≥ 40 mm Hg, or DLCO ≤ 50% predicted with
FVC > 85%, or with DLCO ≥ 20%, or unexplained dys-
pnea), especially in the presence of symptoms and with-
out adequate explanation on high-resolution CT
(HRCT) lung and/or V/Q scanning, are considered for
right-heart catheterization (RHC). The ASCS is
approved by the human research ethics committees of
the 13 participating Australian centers, and patients pro-
vide written informed consent at recruitment.
For inclusion in the present study, we selected four
groups of patients based on data prospectively recorded
in the ASCS database. In group 1, we included 15 con-
secutive patients with RHC confirmed PAH, based on a
mean pulmonary artery pressure (mPAP) ≥ 25 mm Hg
and pulmonary capillary wedge pressure (PCWP) ≤ 15
mm Hg [12]. These patients had no more than minor
changes of ILD on HRCT.
Group 2 (n = 30) consisted of patients who were
deemed “at risk” of SSc-PAH on the basis of sPAPTTE >
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36 mm Hg, and at least one of hemoglobin corrected
DLCO (DLCOcorr) percentage predicted < 50; and/or
FVC/DLCO percentage predicted ≥ 1.6 [12,16]. This
group included nine patients who underwent RHC
because of an sPAPTTE > 43 mm Hg, with the finding of
“borderline PAH” on RHC (mPAP, 20 to 24 mm Hg, and
PCWP, ≤ 15 mm Hg). Group 2 had no evidence of signifi-
cant obstructive airways disease (forced expiratory volume
in 1 second (FEV1, liters)/forced vital capacity (FVC, liters)
percentage predicted > 0.7) or interstitial lung disease on
HRCT lung, and an FVC > 70% predicted.
Group 3 (n = 19) consisted of patients with significant
ILD, defined as moderate or severe changes of ILD on
HRCT, with an FVC < 85% predicted, without evidence
of SSc-PAH on RHC (mPAP, < 25 mm Hg, and PCWP,
≤ 15 mm Hg) or TTE (sPAPTTE, ≤ 36 mm Hg).
Group 4 (n = 30) were SSc controls who did not have
evidence of cardiopulmonary complications, based on
sPAPTTE < 30 mm Hg, normal myocardial function on
TTE, DLCOcorr > 70% predicted, FEV1/FVC percentage
predicted > 0.7, no ILD on HRCT (and in those without
an HRCT, FVC ≥ 80% predicted), and WHO-FC I or II.
All patients selected for groups 2, 3, and 4 were
required to have normal RV function assessed semi-
quantitatively with TTE.
Exclusion criteria for all groups included the presence
of abnormal left ventricular systolic or diastolic function
for age measured at TTE, abnormal left atrial size, an
unrecordable tricuspid regurgitant Doppler signal, and
estimated glomerular filtration rate (eGFR) < 30 ml/min.
Cardiac and pulmonary assessments
Left ventricular systolic and diastolic function was deter-
mined by two-dimensional TTE performed within 3
months of collection of serum for the NT-proBNP
assay. Systolic PAP was estimated by Doppler TTE
(sPAPTTE) at rest, based on peak velocity of the tricus-
pid regurgitant jet and estimation of right atrial pressure
of 5 to 10 mm Hg, based on the diameter and respira-
tory variation of the inferior vena cava. TTE was per-
formed only at tertiary centers for SSc assessment.
Pulmonary involvement was assessed with a pulmonary-
function test (PFT) and/or HRCT within 3 months of
serum collection for the NT-proBNP assay. HRCTs
were reported as no, mild, moderate, or severe ILD by a
radiologist. All DLCOcorr (ml/mm Hg/min) values are
reported as percentage of predicted values, corrected for
hemoglobin [24]. All FEV1 (liters), FVC (liters), and
FVC/DLCOcorr values are reported as percentage pre-
dicted for sex, race, and height.
Serum samples and NT-proBNP measurement
All patients had serum collected for NT-proBNP mea-
surement within 3 months of their annual clinical
assessment and cardiopulmonary investigations. All
PAH patients in group 1 had serum collected for NT-
proBNP measurement at the time of their RHC and
before the commencement of advanced pulmonary vaso-
dilator therapy. Blood samples were collected at rest
into tubes containing EDTA. Samples were centrifuged
and stored at -80°C until used. NT-proBNP was mea-
sured by using the Elecsys proBNP II sandwich immu-
noassay on the modular analytics E170 (Roche
Diagnostics, Mannheim, Germany). The measurement
range of this assay is between 5 pg/ml and 35,000 pg/
ml.
Study design and statistical analysis
In this case-control study, NT-proBNP levels in patients
with PAH (group 1) were compared with those of
patients considered at “at risk” of PAH (group 2), ILD
patients (group 3), and SSc controls (group 4) by using
analysis of variance (ANOVA) with Bonferroni multiple
test comparison correction. NT-proBNP levels were nat-
ural log transformed to satisfy the assumptions of nor-
mality and homogeneity of variance.
Simple linear and multiple linear regression analyses
The correlation between natural log-transformed NT-
proBNP and TTE and RHC measures of cardiopulmon-
ary function was quantified by using the Pearson corre-
lation coefficient and simple linear regression. Multiple
linear regression models were used to determine the
independent correlates of NT-proBNP.
ROC curve analysis
Receiver operator characteristic (ROC) curve analysis
was used for each of four variables (NT-proBNP,
DLCOcorr, FVC/DLCOcorr, and sPAPTTE) to determine
the optimal cut point that maximized desired test prop-
erties. For each variable, comparison groups were PAH
versus controls and PAH versus ILD. For the optimal
cut points, results are presented as sensitivity, specificity,
and positive and negative likelihood ratios, with 95%
confidence intervals (95% CIs). For each variable, area
under the curve (AUC) of sensitivity plotted against 1-
specificity is also reported with 95% CI.
Model development and testing
Based on the ROC curve analysis, we created two mod-
els for PAH prediction. The first model was based solely
on PFT (DLCOcorr and FVC/DLCOcorr ratio). The sec-
ond “composite” model incorporated both NT-proBNP
and PFTs. The properties of these models for discrimi-
nating PAH from controls, and patients with ILD, were
tested by using contingency tables and are presented as
sensitivity, specificity, and positive- and negative-likeli-
hood ratios with surrounding 95% CI.
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Application of models to an “at risk” group
The PAH prediction models developed were applied to
the at-risk group to determine the proportion of these
patients that screened positive.
All statistical analyses were performed by using
STATA 11.0 (Statacorp, College Station, TX, USA).
Results
The clinical characteristics and investigative para-
meters of patients in each group are shown in Tables
1 and 2.
Comparison of NT-proBNP levels between groups
NT-proBNP levels were compared between groups
(Figure 1A). The PAH group had significantly greater
mean NT-proBNP levels compared with the at-risk
group (1,817.6 ± 2,367.0 versus 277.6 ± 242.7 ng/ml;
P < 0.0001), ILD group (133.0 ± 86.6 ng/ml; P <
0.0001 versus Group 1), and the control group (72.1 ±
37.8 ng/ml; P < 0.0001 versus Group 1). Three
patients had NT-proBNP values > 3,000 pg/ml; these
patients had the most severe pulmonary hypertension
at RHC (mPAP, 58.3 ± 6.0 mm Hg; mean right atrial
pressure (mRAP) 13.7 ± 3.5 mm Hg; peripheral vascu-
lar resistance (PVR), 11.0 ± 0.9 Wood units). Further-
more, the results from the at-risk group were
intermediate to the PAH groups and controls, with a
significantly higher mean NT-proBNP level than the
controls (277.6 ± 242.7 versus 72.1 ± 37.8 ng/ml; P <
0.0001).
Correlation of NT-proBNP with sPAPTTE
A significant positive correlation of NT-proBNP levels
with sPAPTTE was found in all groups combined (Figure
1B), with a Pearson correlation coefficient of 0.65 (P <
0.0001). Simple linear regression comparing NT-proBNP
levels in the PAH group and controls showed a signifi-
cant relation between NT-proBNP and sPAPTTE (b =
0.05; 95% CI, 0.04 to 0.06; P < 0.0001). As the PAH
group were older (63.3 ± 10.5 versus 48.7 ± 10.1 years; P
= 0.001) and had a longer disease duration (18.8 ± 13.5
versus 7.8 ± 7.2 years; P = 0.003) compared with controls,
a multivariable model including NT-proBNP, age, disease
duration, and sPAPTTE was used and showed that the
sPAPTTE was independently associated with the NT-
proBNP level (b = 0.05; 95% CI, 0.03 to 0.06; P < 0.001)
but not age (P = 0.19) or disease duration (P = 0.38).
Correlation of NT-proBNP with cardiopulmonary
hemodynamics
A significant positive correlation of NT-proBNP with a
number of important cardiopulmonary parameters on
RHC was found (Figure 2), including mPAP (mm Hg)
(correlation coefficient = 0.63; P = 0.013), PVR (Wood
units; correlation coefficient = 0.76; P = 0.005), and mRAP
(mm Hg; correlation coefficient = 0.77; P = 0.006).
The effects of comorbid illness and treatment on NT-
proBNP levels
In simple linear regression analysis, the use of calcium
channel blockers was not associated with NT-proBNP










Number (n) 15 30 19 30 N/A
Age at onset (years) 44.5 ± 12.9 51.5 ± 14.8 40.3 ± 15.6 40.6 ± 13.2 0.015a
Age at study (years) 63.3 ± 10.5 66.0 ± 11.8 51.1 ± 12.7 48.7 ± 10.1 < 0.0001b
Disease duration (years) 18.8 ± 13.5 14.5 ± 10.4 10.8 ± 7.9 7.8 ± 7.2 0.003c
Female, n (%) 12 (80) 25 (83) 14 (74) 30 (100) 0.04
Male, n (%) 3 (20) 5 (17) 5 (26) 0
Limited (n) 13 28 6 23 < 0.0001d
Diffuse (n) 2 2 13 7
ANA, n 14 27 17 30 0.43
Anti-Scl70, n 1 3 10 5 0.001e
Anti-cent, n 7 21 0 16 < 0.0001f
WHO FC
-I 0 5 0 25 N/A
-II 2 11 12 5
-III 11 14 6 0
-IV 2 0 1 0
Dis. Duration, disease duration; PAH, pulmonary arterial hypertension; WHO FC, World Health Organisation Functional Class; ANA, anti-nuclear antibody; anti-
Scl70, anti- topoisomerase-1 antibody; anti-cent, anti-centromere antibody. aOlder age at SSc onset in at-risk group versus other groups. bOlder age at time of
study in PAH group and at-risk groups versus others. cLonger disease duration at time of study in PAH group versus controls. dHigher proportion of patients with
limited subtype in all groups except ILD. eHigher proportion of Scl-70-positive patients in ILD than other groups. fHigher proportion of centromere-positive
patients in all groups compared with ILD.
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levels in the PAH group (b = -1.33; 95% CI, -2.85 to
0.19; P = 0.082). Furthermore, calcium channel blocker
use was not associated with NT-proBNP levels in multi-
variable models that included markers of PAH severity
(cardiac output (P = 0.273), mRAP (P = 0.209), or PVR
(P = 0.248)). Simple linear regression analysis did not
show renal function (P = 0.654) or body mass index (P
= 0.996) to be associated with NT-proBNP levels in the
PAH group.
ROC curve analysis for single variables
As seen in Table 3, ROC curve analysis for each variable
was performed for PAH versus controls, and PAH ver-
sus ILD. An NT-proBNP cut point of ≥ 209.8 ng/ml for
PAH versus controls had a sensitivity of 92.9% and spe-
cificity of 100%, with a high AUC of 0.93 for diagnosing
PAH. Similarly, an NT-proBNP cut point ≥ 360.5 mg/
ml for PAH versus ILD had a sensitivity of 85.7% and
specificity of 100%, with an AUC of 0.92 for diagnosing
PAH. A DLCOcorr < 70.3% completely segregated PAH
from controls (sensitivity, 100%; specificity, 100%; AUC
= 1.0). However, no optimal cut point for DLCOcorr
could be determined that adequately segregated PAH
from ILD. An FVC/DLCOcorr ≥ 1.66 had a sensitivity of
64.3% and specificity of 96.7%, with an AUC = 0.90 for
PAH versus controls. The FVC/DLCOcorr was higher at
≥ 1.82 for PAH versus ILD, with a sensitivity of 50.0%,
specificity of 94.4%, and an AUC of 0.71 for PAH versus
ILD.
Prediction models and their properties
The results from the ROC curve analyses were used to
form two screening models that were evaluated in PAH
versus controls, and in PAH versus ILD patients (Table
3).
The first model (model 1) was based solely on PFTs.
Here, patients who had DLCOcorr < 70.3% and FVC/
DLCOcorr ratio ≥ 1.82 were regarded as having a “posi-
tive” screen. When applied to compare PAH with con-
trols, this composite model yielded a sensitivity of 50.0%
along with a specificity of 100% for PAH. When applied
to compare PAH with ILD, the sensitivity remained at
50.0% with a specificity of 94.4%.
The second model (model 2) used a composite of
DLCOcorr < 70.3% with FVC/DLCOcorr ≥ 1.82 (compo-
nent A) and NT-proBNP ≥ 209.8 pg/ml (component B).
In this model, the screen was “negative” if both compo-
nent A and component B were negative. The screen was
positive if either component A and/or component B was
positive. This model reliably distinguished PAH from
controls with a sensitivity and specificity of 100%. When
applied to PAH versus ILD groups, the screen yielded a
sensitivity of 100% with a specificity of 77.8% (88% cor-
rect prediction).
Model performance in an at-risk group
When the first model using only PFTs was applied to
the at-risk group, 11 of 29 (37.9%) patients screened
positive for the presence of PAH. Among these 11











TRV (m/s) 3.8 ± 0.7 2.95 ± 0.3 2.54 ± 0.4 2.20 ± 0.2 < 0.0001
sPAP (mm Hg) 65.8 ± 27.3 43.8 ± 7.2 32.1 ± 5.3 26.3 ± 2.6 < 0.0001
RHC results
mPAP (mm Hg) 40.2 ± 12.5 N/A N/A N/A N/A
mRAP (mm Hg) 10.1 ± 3.3 N/A N/A N/A N/A
PVR (Wood units) 6.2 ± 3.4 N/A N/A N/A N/A
PFT
FVC (% pred) 75.5 ± 23.4 100.6 ± 19.5 68.7 ± 13.2 102.8 ± 13.4 < 0.0001a
DLCOcorr (% pred) 45.6 ± 11.7 61.0 ± 15.1 48.0 ± 12.7 86.8 ± 13.0 < 0.0001
b
FVC/DLCOcorr 1.76 ± 0.38 1.73 ± 0.46 1.46 ± 0.31 1.20 ± 0.20 < 0.0001
c
6MWD (m) 337 ± 100 N/A 458 ± 84 N/A N/A
Log NT-proBNP 6.72 ± 1.48 5.18 ± 1.11 4.72 ± 0.57 4.12 ± 0.63 < 0.0001
NT-proBNP (pg/ml) 1818 ± 2367 278 ± 243 133 ± 87 72 ± 38 < 0.0001d
6MWD, 6-minute walk distance; DLCO, diffusion capacity of lung for carbon monoxide (% predicted); FVC, forced vital capacity (% predicted); ILD, interstitial lung
disease; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH, pulmonary arterial
hypertension; PVR, pulmonary vascular resistance; sPAP, systolic pulmonary artery pressure; TRV, tricuspid regurgitant velocity. aLower FVC in PAH and ILD groups,
versus “at risk” and controls
bLower DLCO in PAH and ILD groups, versus “at risk” and controls. cHigher FVC/DLCO in PAH and “at risk” groups, versus ILD and controls. dHigher NT-ProBNP in
PAH versus other groups, and “at risk” versus controls.
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patients, the mean sPAPTTE was 41.9 mm Hg (SD,
6.99).
When the second model was applied to the at-risk
group, 17 of 29 (58.6%) patients screened positive for
the presence of PAH. Among these 17 patients, mean
sPAPTTE was 44.4 mm Hg (SD, 8.2).
The at-risk group had a subset of nine patients with a
borderline RHC mPAP of 20 to 24 mm Hg who collec-
tively had a mean sPAPTTE of 49.4 mm Hg (SD, 9.1). Of
these nine patients, seven (77.7%) were screened positive.
Of the remaining 20 patients in the at-risk group, who
had not yet consented to RHC, 10 (50%) were screened
positive, with a mean sPAPTTE of 41.4 mm Hg (SD, 4.6)
Discussion
In this study, we showed that NT-proBNP, particularly
when combined with PFTs, has the potential for use as
a screening algorithm for PAH in patients with SSc,
with “screen positive” patients then able to undergo
further appropriate diagnostic testing. We also showed
that NT-proBNP level correlates well with screening
sPAPTTE, which is currently regarded as the most useful
noninvasive method of screening for PAH. However, a
number of important limitations of TTE are related to
the lack of sufficient tricuspid regurgitation to estimate
sPAPTTE, insufficient reliability in the context of coexis-
tent lung disease, potential poor acoustic windows
related to body habitus, the need for specific expertise
in technique and interpretation, as well as issues related
to cost and resource allocation [14,17]. It is against
these limitations of echocardiography that NT-proBNP
and PFTs in combination offer an accurate and more
convenient “first tier” of screening tests for SSc patients.
In Figure 3, we have proposed a screening algorithm
for SSc-PAH based on the findings of this study. In this
screening algorithm, TTE is replaced by PFTs and NT-
proBNP as the first tier of screening investigations.
Thus only patients who have either DLCOcorr < 70.3%
with FVC/DLCOcorr ≥ 1.82, or NT-proBNP ≥ 209.8 pg/
ml, or both, proceed to TTE, whereas those with
DLCOcorr ≥ 70.3% and FVC/DLCO < 1.82 and NT-
proBNP < 209.8 pg/ml are reassured and have repeated
screening. If a patient is deemed to have a high clinical
suggestion of PAH, then it would be appropriate to per-
form diagnostic tests to confirm or exclude PAH. The
inclusion of PFTs (including FEV1, FVC, and DLCO) in
the first tier of investigations also enables detection of
patients with probable ILD who may require further
investigation with HRCT.
Although we found that a sPAPTTE cut point of > 42
mm Hg had a 100% sensitivity and specificity for PAH,
we are unable to recommend this diagnostic cut point,
as the control group in our study were selected on the
basis of a sPAPTTE < 30 mm Hg. In other studies, a
lower cut-off point of sPAPTTE > 30 mm Hg had a sen-
sitivity of 90%, whereas a higher cut-off point of
sPAPTTE > 47 mm Hg had a specificity of 96% for PAH
[15,17].
In this study, we demonstrated a correlation of NT-
proBNP with key diagnostic and prognostic RHC para-
meters, including mPAP, mRAP, and PVR [20,25]. As
RHC is the current gold-standard confirmatory investi-
gation for PAH, these positive correlations again support
the usefulness of NT-proBNP as a biomarker in SSc-
PAH.
In the present study, we found a low or “normal” NT-
proBNP level in all controls, but one patient with PAH
Figure 1 Comparison of Nt-proBNP level among groups and
correlation with sPAP on transthoracic echocardiography. (A)
NT-proBNP levels are significantly higher in the PAH group
compared with “at risk,” ILD, and control groups. Levels in the at-risk
group are significantly higher than those in the control group. (B)
NT-proBNP levels have a significant positive correlation with
screening sPAP across all groups. NT-proBNP, N-terminal pro-brain
natriuretic peptide; PAH, pulmonary arterial hypertension; ILD,
interstitial lung disease; sPAP, systolic pulmonary artery pressure on
transthoracic echocardiography (mm Hg); log, natural log; r, Pearson
coefficient.
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had an NT-proBNP level below the cut point of 209.8
pg/ml. Such “false negatives” also were seen in a study
from the Royal Free Hospital in the UK, which showed
an NT-proBNP cut-point value of 395 pg/ml to have a
sensitivity of 69% for PAH in a pilot study; this cut-
point value was then separately tested in a larger
Figure 2 Correlation of NT-proBNP with RHC parameters. In patients with PAH, NT-proBNP levels have a significant positive correlation with
RHC parameters of (A) mPAP; (B) mRAP; and (C) PVR. NT-proBNP, N-terminal pro-brain natriuretic peptide; mPAP, mean pulmonary artery
pressure (mm Hg); mRAP, mean right atrial pressure (mm Hg); PVR, pulmonary vascular resistance (Wood units); PAH, pulmonary arterial
hypertension; Log, natural log; r, Pearson coefficient.
Table 3 Results of ROC curve analysis and contingency table analysis for NT-proBNP and PFT
Variable Comparison
groups




























PAH versus ILD Nil - - - - 0.42
(0.22-0.63)








































DLCO < 70.3% and
FVC/DLCO ≥ 1.82 (A)
and/or
NT-proBNP ≥ 209.8 (B)












DLCO, diffusing capacity of lungs for carbon monoxide, % predicted; FVC, forced vital capacity, % predicted; ILD, interstitial lung disease; NT-proBNP, N-terminal
pro brain natriuretic peptide; PAH, pulmonary arterial hypertension; (A) and (B) refer to the two components of the “composite” screening model. aBecause of the
relatively small sample size, the upper limit of the 95% CI approximates but does not equal 100%.
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prospective case-control study that produced a sensitiv-
ity of only 55.9% [20,25]. The reasons for these false
negatives are unknown, but may include the interference
of glycosylation with the NT-proBNP assay [26]. In our
study, the patient with PAH and a low NT-proBNP had
poor glycemic control. To overcome the potential pro-
blem of false negatives with NT-proBNP, we combined
this biomarker with PFT. When combined with PFT,
the NT-proBNP cut point of 209.8 pg/ml offered the
excellent sensitivity (100%) for PAH that is desirable in
a screening initiative. In the study by Mukerjee et al.
[20], in which a higher NT-proBNP level of 395 pg/ml
was determined as the cut point for PAH than in our
study, 11 of 26 controls were undergoing the investiga-
tion for breathlessness, the cause of which may have led
to a higher cut-point NT-proBNP level. In the subse-
quent validation study by Williams et al. [25], it is possi-
ble that the NT-proBNP cut point of 395 pg/ml was
partly due to at least 20% of controls having ILD, which
is in line with the findings from our study that suggest a
higher NT-proBNP cut point (≥ 360.5 pg/ml) is required
to separate PAH from ILD groups.
Our study has a number of strengths. The first is that
all sera were assayed for NT-proBNP before the com-
mencement of advanced therapies in a population newly
diagnosed with PAH. Second, the inclusion of an ILD
group offers a challenging and real-life complexity.
Together, PAH and ILD account for more than 60% of
SSc-related deaths, and the poorer prognosis of patients
with ILD who also develop PAH is increasingly recog-
nized [1,27]. Although a significantly higher mean NT-
proBNP level was seen in the PAH group compared
with the ILD group, a higher NT-proBNP cut point was
required to separate the PAH group from the ILD
group. This implies that ILD alone may result in modest
elevation of NT-proBNP. These findings are consistent
with those reported in studies of BNP that included
SSc-ILD patients, suggesting modestly increased BNP in
ILD patients without PAH [28]. Further, increased BNP
levels are associated with greater mortality in ILD
patients with coexistent PAH [28,29]. Alternatively, the
higher cut point in the PAH-versus-ILD groups may
reflect a degree of undiagnosed pulmonary hypertension
and right ventricular compromise in the ILD group. For
the purposes of screening, the addition of an FVC/
DLCO cut point to the lower threshold value of NT-
proBNP (209.8 pg/ml) incorporates an easy-to-calculate,
inexpensive, and potentially useful clinical tool that can
suggest the presence of pulmonary vascular disease.
The application of the screening model to the sub-
group of at-risk patients with “borderline” pulmonary
hypertension (that is, mPAP, 20 to 24 mm Hg, and
PCWP, ≤ 15 mm Hg) who do not currently satisfy Dana
Point criteria for PAH, revealed that a high proportion
of these patients (77.7%) would have screened positive.
Although the natural history of this group requires
further longitudinal study, the high sensitivity of the
algorithm in a group of patients that would be regarded
as having abnormal pulmonary pressures, and possibly
evolving PAH, is encouraging and is required of a
screening tool [30].
Potential limitations of this pilot study may affect the
generalizability of the findings. We have not included
patients with left ventricular (LV) dysfunction, a factor
that can increase the level of NT-proBNP. However, it
is important to note that in our proposed screening
algorithm, all patients with a positive NT-proBNP
would progress to TTE to evaluate further for LV dys-
function and valvular heart disease. The goal of this
screening algorithm is not to distinguish between PAH
and left ventricular dysfunction but to select patients
who may be developing cardiopulmonary complications
for further investigations.
In this study, we also excluded patients with an eGFR
< 30 ml/min, given the reduced renal excretion of NT-
proBNP at these levels. However, with significant renal
impairment, one would expect an increase in NT-
proBNP, meaning a possible increase in false-positive
screens but not an increase in false-negative screens.
SSc patient 
DLCOcorr < 70.3 & 
FVC/DLCO  1.82 
And/Or 
NT-proBNP > 209.8 pg/ml  





Low likelihood of PAH 
DLCOcorr  70.3 & 
FVC/DLCO < 1.82 
And 
NT-proBNP  209.8 pg/ml  
Right Heart Catherisation 





Figure 3 A proposed screening algorithm for SSc-PAH. 6MWT,
6-minute walk test; DLCO, diffusion capacity of lungs to carbon
monoxide, percentage predicted; FVC, forced vital capacity,
percentage predicted; HRCT, high-resolution computed tomography
of lung; NT-proBNP, N-terminal pro-brain natriuretic peptide (pg/ml);
PAH, pulmonary arterial hypertension; PFT, pulmonary-function test;
SSc, systemic sclerosis.
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Further, this degree of renal compromise is not fre-
quently seen in SSc patients.
Last, the study is limited by the relatively small size in
each group and its observational case-control design.
The prospective evaluation of this algorithm in a cohort
of SSc patients is required to refine screening cut points,
validate the model, assess predictive values, and deter-
mine the frequency of screening.
The cost-effectiveness of our proposed screening algo-
rithm also merits evaluation. At present, the cost of
TTE combined with PFT in Australia is approximately
$A367, whereas the cost of the PFT combined with NT-
proBNP assay is $A195. Therefore, potentially, our pro-
posed screening algorithm may lead to a cost saving in
screening for SSc-PAH, compared with the existing
screening algorithm. Furthermore, NT-proBNP assays
have become more clinically available with the wide-
spread use of NT-proBNP in the diagnosis, prognosis,
and risk stratification of patients with congestive cardiac
failure.
Conclusions
We propose the prospective validation of a screening
algorithm for PAH that is considered positive if either
NT-proBNP ≥ 209.8 pg/ml, or DLCOcorr < 70.3% with
FVC/DLCOcorr ≥ 1.82, or both. Patients who screen
positive should be referred for TTE and considered for
additional investigations, such as HRCT or 6MWT, and
RHC, if appropriate.
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